New, improved treatments for Chagas disease: From the R&D pipeline to the patients

PLoS Neglected Tropical Diseases

Volumn 3, Issue 7, 2009, Pages

  Ribeiro, Isabela ^a   Sevcsik, Ann Marie ^a   Alves, Fabiana ^a   Diap, Graciela ^a   Don, Robert ^a   Harhay, Michael O ^b   Chang, Shing ^a   Pecoul, Bernard ^a  

^a Drugs for Neglected Diseases Initiative   (Switzerland)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 4 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL] 1,2,4 TRIAZOL 3(2H) ONE; ANTITRYPANOSOMAL AGENT; BENZNIDAZOLE; CANTHIN 6 ONE; DIHYDROFOLATE REDUCTASE INHIBITOR; DNA TOPOISOMERASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; LIGNAN; NAPHTHOQUINONE; NIFURTIMOX; POSACONAZOLE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEINASE INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAVUCONAZOLE; SQUALENE SYNTHASE INHIBITOR; TRANSFERASE INHIBITOR; VORICONAZOLE; ANTIPROTOZOAL AGENT;

BLOOD ANALYSIS; BLOOD CULTURE; CHAGAS DISEASE; CLINICAL RESEARCH; COOPERATION; DRUG FORMULATION; DRUG RESEARCH; HEALTH CARE ACCESS; HIGH THROUGHPUT SCREENING; HUMAN; METHODOLOGY; MICROSCOPY; NON PROFIT ORGANIZATION; NONHUMAN; PATHOGENESIS; PATIENT COMPLIANCE; POINT OF CARE TESTING; POLYMERASE CHAIN REACTION; REVIEW; TREATMENT DURATION; TRYPANOSOMA CRUZI; UNSPECIFIED SIDE EFFECT; WORLD HEALTH ORGANIZATION; XENODIAGNOSIS; CLINICAL TRIAL; DRUG DEVELOPMENT; DRUG SCREENING; MEDICAL RESEARCH; TIME;

ANTIPROTOZOAL AGENTS; BIOMEDICAL RESEARCH; CHAGAS DISEASE; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; TIME FACTORS;

EID: 70449562088     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000484     Document Type: Review

References (58)

1. World Health Organization (2004) World health report 2004. Changing history. Geneva: World Health Organization.
2. Hotez PJ, Bottazzi ME, Franco-Paredes C, Ault SK, Periago MR (2008) The neglected tropical diseases of Latin America and the Caribbean: a review of disease burden and distribution and a roadmap for control and elimination. PLoS Negl Trop Dis 2: e300. doi:10.1371/journal.pntd.0000300.
3. Chagas C (1909) Novo Tripanozomiaze humana. Estudos sobre a morfologia e o ciclo evolutivo do Schizotrypanum cruzi n.gen., n.sp., ajente etiolojico de nova entidade morbida do homem. Mem Inst Oswaldo Cruz 1: 159-218.
4. Tarleton RL, Reithinger R, Urbina JA, Kitron U, Gurtler RE (2007) The challenges of Chagas disease-grim outlook or glimmer of hope. PLoS Med 4: e332. doi/10.1371/journal.pmed.0040332.
5. Hotez PJ (2007) Neglected diseases and poverty in "the other America": the greatest health disparity in the United States? PLoS Negl Trop Dis 1: e149. doi:10.1371/journal.pntd.0000149.
6. Mathers CD, Ezzati M, Lopez AD (2007) Measuring the burden of neglected tropical diseases: the global burden of disease framework. PLoS Negl Trop Dis 1: e114. doi:10.1371/journal.pntd.0000149. (Pubitemid 352024647)
7. Moncayo A, Ortiz Yanine MI (2006) An update on Chagas disease (human American trypanosomiasis). Ann Trop Med Parasitol 100: 663-677. (Pubitemid 46940906)
8. Pan-American Health Organization/World Health Organization (2005) Reporte del grupo de trabajo cientifico sobre la enfermedad de Chagas. Buenos Aires: WHO/PAHO.
9. Schmunis GA, Cruz JR (2005) Safety of the blood supply in Latin America. Clin Microbiol Rev 18: 12-29. (Pubitemid 40170659)
10. Dias JC, Silveira AC, Schofield CJ (2002) The impact of Chagas disease control in Latin America: a review. Mem Inst Oswaldo Cruz 97: 603-612.
11. Dias JC (2007) Southern Cone Initiative for the elimination of domestic populations of Triatoma infestans and the interruption of transfusional Chagas disease. Historical aspects, present situation, and perspectives. Mem Inst Oswaldo Cruz 102 Suppl 1: 11-18.
12. Guhl F (2007) Chagas disease in Andean countries. Mem Inst Oswaldo Cruz 102 Suppl 1: 29-38.
13. Villela MM, Souza JM, Melo Vde P, Dias JC (2009) Evaluation of the Chagas Disease Control Program and presence of Panstrongylus megistus in central-western Minas Gerais State, Brazil. Cad Saude Publica 25: 907-917.
14. Dumonteil E, Gourbiere S, Barrera-Perez M, et al. (2002) Geographic distribution of Triatoma dimidiata and transmission dynamics of Trypanosoma cruzi in the Yucatan peninsula of Mexico. Am J Trop Med Hyg 67: 176-183. (Pubitemid 135715333)
15. Pereira KS, Schmidt FL, Guaraldo AM, Franco RM, Dias VL, Passos LA (2009) Chagas' disease as a foodborne illness. J Food Prot 72: 441-446.
16. Schmunis GA (2007) Epidemiology of Chagas disease in non-endemic countries: the role of international migration. Mem Inst Oswaldo Cruz 102 Suppl 1: 75-85.
17. de-Ayala AP, Perez-Molina JA, Norman F, Lopez-Velez R (2009) Chagasic cardiomyopathy in immigrants from Latin America to Spain. Emerg Infect Dis 15: 607-608.
18. Jackson Y, Myers C, Diana A, Marti HP, Wolff H, et al. (2009) Congenital transmission of Chagas disease in Latin American immigrants in Switzerland. Emerg Infect Dis 15: 601-603.
19. FDA/CDER (March 2009) Draft guidance for industry: use of serological tests to reduce the risk of transmission of Trypanosoma cruzi infection in whole blood and blood components for transfusion and human cells, tissues, and cellular and tissue-based products (HCT/Ps). Silver Spring (Maryland): Food and Drug Administration, US Department of Health and Human Services.
20. Parada H, Carrasco HA, Anez N, Fuenmayor C, Inglessis I (1997) Cardiac involvement is a constant finding in acute Chagas' disease: a clinical, parasitological and histopathological study. Int J Cardiol 60: 49-54. (Pubitemid 27288256)
21. Pinto AY, Valente SA, Valente Vda C (2004) Emerging acute Chagas disease in Amazonian Brazil: case reports with serious cardiac involvement. Braz J Infect Dis 8: 454-460.
22. Prata A (2001) Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis 1: 92-100. (Pubitemid 33586044)
23. Pinto Dias JC (1995) [Natural history of Chagas disease]. Arq Bras Cardiol 65: 359-366.
24. Bern C, Montgomery SP, Herwaldt BL, Rassi A Jr, Marin-Neto JA, et al. (2007) Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA 298: 2171-2181. (Pubitemid 350106656)
25. de Andrade AL, Zicker F, de Oliveira RM, Almeida Silva S, Luquetti A, et al. (1996) Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 348: 1407-1413. (Pubitemid 26395235)
26. Villar JC, Marin-Neto JA, Ebrahim S, Yusuf S (2002) Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database Syst Rev. pp CD003463.
27. Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, et al. (2006) Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 144: 724-734. (Pubitemid 46780632)
28. Reyes PA, Vallejo M (2005) Trypanocidal drugs for late stage, symptomatic Chagas disease (Trypanosoma cruzi infection). Cochrane Database Syst Rev. pp CD004102.
29. Marin-Neto JA, Rassi A Jr, Morillo CA, Avezum A, Connolly SJ, et al. (2008) Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J 156: 37-43. (Pubitemid 351862295)
30. Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, et al. (1998) Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am J Trop Med Hyg 59: 526-529. (Pubitemid 28480704)
31. Coura JR, de Abreu LL, Willcox HP, Petana W (1997) [Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas' disease, in a field area with interrupted transmission. I. Preliminary evaluation]. Rev Soc Bras Med Trop 30: 139-144.
32. Urbina JA, Docampo R (2003) Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol 19: 495-501.
33. Atwood JA 3rd, Weatherly DB, Minning TA, Bundy B, Cavola C, et al. (2005) The Trypanosoma cruzi proteome. Science 309: 473-476.
34. El-Sayed NM, Myler PJ, Bartholomeu DC, Nilsson D, Aggarwal G, et al. (2005) The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. Science 309: 409-415. (Pubitemid 40994675)
35. WHO (2009) Chagas disease: control and elimination. Report of the Secretariat to the Executive Board, 124th Session. Available: http://apps.who.int/gb/ebwha/pdf-files/EB124/B124-17-en.pdf. Accessed 16 June 2009.
36. Pecoul B (2004) New drugs for neglected diseases: from pipeline to patients. PLoS Med 1: e6. doi:10.1371/journal.pmed.0010006.
37. Nwaka S, Ridley RG (2003) Virtual drug discovery and development for neglected diseases through public-private partnerships. Nat Rev Drug Discov 2: 919-928. (Pubitemid 37419900)
38. Doyle PS, Zhou YM, Engel JC, McKerrow JH (2007) A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection. Antimicrob Agents Chemother 51: 3932-3939.
39. Engel JC, Doyle PS, McKerrow JH (1999) [Trypanocidal effect of cysteine protease inhibitors in vitro and in vivo in experimental Chagas disease]. Medicina (B Aires) 59 Suppl 2: 171-175.
40. Jonckers TH, van Miert S, Cimanga K, Bailly C, Colson P, et al. (2002) Synthesis, cytotoxicity, and antiplasmodial and antitrypanosomal activity of new neocryptolepine derivatives. J Med Chem 45: 3497-3508. (Pubitemid 34824038)
41. Buckner F, Yokoyama K, Lockman J, Aikenhead K, Ohkanda J, et al. (2003) A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents. Proc Natl Acad Sci U S A 100: 15149-15153. (Pubitemid 37518031)
42. Buckner FS (2008) Sterol 14-demethylase inhibitors for Trypanosoma cruzi infections. Adv Exp Med Biol 625: 61-80.
43. Sealey-Cardona M, Cammerer S, Jones S, Ruiz-Perez LM, Brun R, et al. (2007) Kinetic characterization of squalene synthase from Trypanosoma cruzi: selective inhibition by quinuclidine derivatives. Antimicrob Agents Chemother 51: 2123-2129. (Pubitemid 46903104)
44. Szajnman SH, Ravaschino EL, Docampo R, Rodriguez JB (2005) Synthesis and biological evaluation of 1-amino-1,1-bisphosphonates derived from fatty acids against Trypanosoma cruzi targeting farnesyl pyrophosphate synthase. Bioorg Med Chem Lett 15: 4685-4690. (Pubitemid 41356662)
45. Hucke O, Gelb MH, Verlinde CL, Buckner FS (2005) The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease. J Med Chem 48: 5415-5418. (Pubitemid 41209239)
46. Kraus JM, Verlinde CL, Karimi M, Lepesheva GI, Gelb MH, et al. (2009) Rational modification of a candidate cancer drug for use against Chagas disease. J Med Chem 52: 1639-1647.
47. Schormann N, Senkovich O, Walker K, Wright DL, Anderson AC, et al. (2008) Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function. Proteins 73: 889-901.
48. Urbina JA (2002) Chemotherapy of Chagas disease. Curr Pharm Des 8: 287-295.
49. Duschak VG, Couto AS (2007) An insight on targets and patented drugs for chemotherapy of Chagas disease. Recent Patents Anti-Infect Drug Disc 2: 19-51.
50. Ioset JR (2008) Natural products for neglected diseases: a review. Curr Org Chem 12: 643-646.
51. Zulantay I, Honores P, Solari A, Apt W, Ortiz S, et al. (2004) Use of polymerase chain reaction (PCR) and hybridization assays to detect Trypanosoma cruzi in chronic chagasic patients treated with itraconazole or allopurinol. Diagn Microbiol Infect Dis 48: 253-257. (Pubitemid 38519582)
52. Molina J, Martins-Filho O, Brener Z, Romanha AJ, Loebenberg D, et al. (2000) Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob Agents Chemother 44: 150-155. (Pubitemid 30010686)
53. Urbina JA, Payares G, Sanoja C, Lira R, Romanha AJ (2003) In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Int J Antimicrob Agents 21: 27-38.
54. Urbina JA, Payares G, Sanoja C, Molina J, Lira R, et al. (2003) Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains. Int J Antimicrob Agents 21: 39-48. (Pubitemid 36043973)
55. Remme JHFea (2006) Tropical diseases targeted for elimination: Chagas disease, lymphatic filariasis, onchocerciasis and leprosy. Disease control priorities in developing countries. 2nd edition. New York: World Bank/Oxford University Press. pp 433-449.
56. Kiechel JR, Pecoul B (2007) [ASAQ, a breakthrough in the fight against malaria]. Med Trop (Mars) 67: 109-110.
57. Moran M (2005) A breakthrough in R&D for neglected diseases: new ways to get the drugs we need. PLoS Med 2: e302. doi/10.1371/journal.pmed.0020302.
58. Moran M, Guzman J, Ropars AL, McDonald A, Jameson N, et al. (2009) Neglected disease research and development: how much are we really spending? PLoS Med 6: e30. doi:10.1371/journal.pmed.1000030.